BioCryst Pharmaceuticals, Inc. (BCRX)
USD 6.8
(-7.23%)
USD 6.8
(-7.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 736.26 Million USD | 68.6% |
| 2022 | 436.68 Million USD | 391.49% |
| 2021 | 88.84 Million USD | 160.27% |
| 2020 | -147.41 Million USD | -399.37% |
| 2019 | -29.51 Million USD | -184.12% |
| 2018 | 35.09 Million USD | 690.36% |
| 2017 | 4.44 Million USD | -85.96% |
| 2016 | 31.62 Million USD | 809.67% |
| 2015 | 3.47 Million USD | 114.16% |
| 2014 | -24.54 Million USD | -377.73% |
| 2013 | 8.83 Million USD | -3.0% |
| 2012 | 9.1 Million USD | -32.8% |
| 2011 | 13.55 Million USD | 199.51% |
| 2010 | -13.62 Million USD | 66.88% |
| 2009 | -41.12 Million USD | -84.07% |
| 2008 | -22.34 Million USD | 28.29% |
| 2007 | -31.15 Million USD | -605.27% |
| 2006 | -4.41 Million USD | 84.85% |
| 2005 | -29.15 Million USD | -229.89% |
| 2004 | -8.83 Million USD | 25.98% |
| 2003 | -11.94 Million USD | 13.62% |
| 2002 | -13.82 Million USD | 26.72% |
| 2001 | -18.86 Million USD | -123.36% |
| 2000 | -8.44 Million USD | 1.79% |
| 1999 | -8.6 Million USD | 30.08% |
| 1998 | -12.3 Million USD | -232.43% |
| 1997 | -3.7 Million USD | -12.12% |
| 1996 | -3.3 Million USD | 40.0% |
| 1995 | -5.5 Million USD | -205.56% |
| 1994 | -1.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 742.54 Million USD | 0.85% |
| 2024 Q2 | 770.43 Million USD | 3.76% |
| 2024 Q3 | -83.81 Million USD | -7.55% |
| 2023 Q1 | -149.2 Million USD | -134.17% |
| 2023 Q3 | -140.93 Million USD | -0.38% |
| 2023 Q2 | -140.41 Million USD | 5.89% |
| 2023 FY | 736.26 Million USD | 68.6% |
| 2023 Q4 | 736.26 Million USD | 622.4% |
| 2022 Q4 | 436.68 Million USD | -8.05% |
| 2022 FY | 436.68 Million USD | 391.49% |
| 2022 Q2 | -119.72 Million USD | -155.05% |
| 2022 Q3 | 474.91 Million USD | 496.68% |
| 2022 Q1 | 217.49 Million USD | 144.79% |
| 2021 FY | 88.84 Million USD | 160.27% |
| 2021 Q1 | -68.97 Million USD | 53.21% |
| 2021 Q2 | -48.43 Million USD | 29.78% |
| 2021 Q3 | -31.06 Million USD | 35.88% |
| 2021 Q4 | 88.84 Million USD | 386.06% |
| 2020 Q2 | -87.98 Million USD | -428.99% |
| 2020 FY | -147.41 Million USD | -399.37% |
| 2020 Q1 | -16.63 Million USD | 43.65% |
| 2020 Q3 | -15.71 Million USD | 82.14% |
| 2020 Q4 | -147.41 Million USD | -837.9% |
| 2019 FY | -29.51 Million USD | -184.12% |
| 2019 Q2 | 52.17 Million USD | 18.45% |
| 2019 Q3 | 54.62 Million USD | 4.7% |
| 2019 Q4 | -29.51 Million USD | -154.04% |
| 2019 Q1 | 44.04 Million USD | 25.51% |
| 2018 Q3 | 9.11 Million USD | -62.94% |
| 2018 FY | 35.09 Million USD | 690.36% |
| 2018 Q4 | 35.09 Million USD | 285.12% |
| 2018 Q2 | 24.58 Million USD | 160.36% |
| 2018 Q1 | 9.44 Million USD | 112.68% |
| 2017 FY | 4.44 Million USD | -85.96% |
| 2017 Q4 | 4.44 Million USD | 107.02% |
| 2017 Q3 | -63.25 Million USD | -537.24% |
| 2017 Q2 | 14.46 Million USD | 168.2% |
| 2017 Q1 | -21.21 Million USD | -167.09% |
| 2016 Q4 | 31.62 Million USD | 74.83% |
| 2016 FY | 31.62 Million USD | 809.67% |
| 2016 Q2 | 21.95 Million USD | 25.31% |
| 2016 Q3 | 18.08 Million USD | -17.61% |
| 2016 Q1 | 17.51 Million USD | 403.97% |
| 2015 FY | 3.47 Million USD | 114.16% |
| 2015 Q1 | -18.36 Million USD | 25.15% |
| 2015 Q3 | -16.62 Million USD | 64.46% |
| 2015 Q2 | -46.78 Million USD | -154.7% |
| 2015 Q4 | 3.47 Million USD | 120.91% |
| 2014 Q3 | -91.15 Million USD | 0.4% |
| 2014 FY | -24.54 Million USD | -377.73% |
| 2014 Q2 | -91.51 Million USD | -657.5% |
| 2014 Q1 | 16.41 Million USD | 85.79% |
| 2014 Q4 | -24.54 Million USD | 73.08% |
| 2013 Q3 | 3.95 Million USD | -61.4% |
| 2013 Q4 | 8.83 Million USD | 123.7% |
| 2013 Q2 | 10.23 Million USD | -32.66% |
| 2013 Q1 | 15.19 Million USD | 66.81% |
| 2013 FY | 8.83 Million USD | -3.0% |
| 2012 Q1 | 2.33 Million USD | -82.75% |
| 2012 Q2 | 8.07 Million USD | 245.28% |
| 2012 Q3 | 6.04 Million USD | -25.2% |
| 2012 Q4 | 9.1 Million USD | 50.79% |
| 2012 FY | 9.1 Million USD | -32.8% |
| 2011 Q1 | -1.34 Million USD | 90.15% |
| 2011 Q2 | 12.99 Million USD | 1068.11% |
| 2011 FY | 13.55 Million USD | 199.51% |
| 2011 Q3 | 7.55 Million USD | -41.82% |
| 2011 Q4 | 13.55 Million USD | 79.34% |
| 2010 Q2 | -14.02 Million USD | 29.46% |
| 2010 FY | -13.62 Million USD | 66.88% |
| 2010 Q1 | -19.87 Million USD | 51.67% |
| 2010 Q4 | -13.62 Million USD | -21.91% |
| 2010 Q3 | -11.17 Million USD | 20.31% |
| 2009 Q2 | -13.81 Million USD | 15.3% |
| 2009 FY | -41.12 Million USD | -84.07% |
| 2009 Q3 | -18.22 Million USD | -31.98% |
| 2009 Q4 | -41.12 Million USD | -125.64% |
| 2009 Q1 | -16.3 Million USD | 27.02% |
| 2008 Q4 | -22.34 Million USD | -40.06% |
| 2008 FY | -22.34 Million USD | 28.29% |
| 2008 Q1 | -27.87 Million USD | 10.53% |
| 2008 Q2 | -25.14 Million USD | 9.81% |
| 2008 Q3 | -15.95 Million USD | 36.55% |
| 2007 Q2 | -7.17 Million USD | 22.04% |
| 2007 Q1 | -9.2 Million USD | -108.42% |
| 2007 FY | -31.15 Million USD | -605.27% |
| 2007 Q4 | -31.15 Million USD | 29.34% |
| 2007 Q3 | -44.09 Million USD | -514.27% |
| 2006 FY | -4.41 Million USD | 84.85% |
| 2006 Q4 | -4.41 Million USD | 42.87% |
| 2006 Q1 | -43.01 Million USD | -47.53% |
| 2006 Q2 | -25.05 Million USD | 41.75% |
| 2006 Q3 | -7.73 Million USD | 69.14% |
| 2005 Q2 | -9.24 Million USD | 58.09% |
| 2005 Q4 | -29.15 Million USD | -220.51% |
| 2005 FY | -29.15 Million USD | -229.89% |
| 2005 Q1 | -22.04 Million USD | -149.47% |
| 2005 Q3 | -9.09 Million USD | 1.55% |
| 2004 FY | -8.83 Million USD | 25.98% |
| 2004 Q1 | -21.05 Million USD | -76.36% |
| 2004 Q4 | -8.83 Million USD | 35.99% |
| 2004 Q2 | -17.04 Million USD | 19.06% |
| 2004 Q3 | -13.8 Million USD | 18.99% |
| 2003 Q4 | -11.94 Million USD | -10.27% |
| 2003 Q3 | -10.82 Million USD | 22.39% |
| 2003 Q2 | -13.95 Million USD | -19.96% |
| 2003 Q1 | -11.63 Million USD | 15.87% |
| 2003 FY | -11.94 Million USD | 13.62% |
| 2002 Q2 | -14.83 Million USD | 20.42% |
| 2002 FY | -13.82 Million USD | 26.72% |
| 2002 Q3 | -13.53 Million USD | 8.72% |
| 2002 Q1 | -18.63 Million USD | 1.22% |
| 2002 Q4 | -13.82 Million USD | -2.12% |
| 2001 Q2 | -17.96 Million USD | -8.17% |
| 2001 FY | -18.86 Million USD | -123.36% |
| 2001 Q3 | -19.4 Million USD | -8.01% |
| 2001 Q4 | -18.86 Million USD | 2.77% |
| 2001 Q1 | -16.6 Million USD | -96.63% |
| 2000 Q3 | -8.75 Million USD | 3.21% |
| 2000 Q4 | -8.44 Million USD | 3.55% |
| 2000 Q1 | -9.75 Million USD | -13.46% |
| 2000 FY | -8.44 Million USD | 1.79% |
| 2000 Q2 | -9.04 Million USD | 7.28% |
| 1999 Q4 | -8.6 Million USD | -38.71% |
| 1999 FY | -8.6 Million USD | 30.08% |
| 1999 Q1 | -8.2 Million USD | 33.33% |
| 1999 Q2 | -5.3 Million USD | 35.37% |
| 1999 Q3 | -6.2 Million USD | -16.98% |
| 1998 FY | -12.3 Million USD | -232.43% |
| 1998 Q1 | -3.4 Million USD | 8.11% |
| 1998 Q2 | -3.6 Million USD | -5.88% |
| 1998 Q3 | -4.9 Million USD | -36.11% |
| 1998 Q4 | -12.3 Million USD | -151.02% |
| 1997 Q2 | -4.5 Million USD | -40.63% |
| 1997 Q4 | -3.7 Million USD | 32.73% |
| 1997 Q3 | -5.5 Million USD | -22.22% |
| 1997 Q1 | -3.2 Million USD | 3.03% |
| 1997 FY | -3.7 Million USD | -12.12% |
| 1996 Q3 | -6.1 Million USD | -3.39% |
| 1996 Q2 | -5.9 Million USD | 35.16% |
| 1996 Q1 | -9.1 Million USD | -65.45% |
| 1996 Q4 | -3.3 Million USD | 45.9% |
| 1996 FY | -3.3 Million USD | 40.0% |
| 1995 Q4 | -5.5 Million USD | 55.28% |
| 1995 FY | -5.5 Million USD | -205.56% |
| 1995 Q1 | -1.1 Million USD | 38.89% |
| 1995 Q2 | -13.9 Million USD | -1163.64% |
| 1995 Q3 | -12.3 Million USD | 11.51% |
| 1994 Q3 | -3.8 Million USD | -80.95% |
| 1994 Q4 | -1.8 Million USD | 52.63% |
| 1994 FY | -1.8 Million USD | 0.0% |
| 1994 Q2 | -2.1 Million USD | 61.82% |
| 1994 Q1 | -5.5 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 1416.171% |
| Alkermes plc | -166.73 Million USD | 541.568% |
| Agenus Inc. | 274.13 Million USD | -168.577% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 60.626% |
| Aptorum Group Limited | 1.35 Million USD | -54155.051% |
| Ardelyx, Inc. | 34.51 Million USD | -2033.362% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -17102.477% |
| Bicycle Therapeutics plc | -481.46 Million USD | 252.921% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -1935.965% |
| ChromaDex Corporation | -24.04 Million USD | 3161.652% |
| Chimerix, Inc. | -25.51 Million USD | 2985.394% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -10466.274% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 3209.625% |
| CRISPR Therapeutics AG | -150.84 Million USD | 588.094% |
| Precision BioSciences, Inc. | -85.41 Million USD | 962.037% |
| Dyadic International, Inc. | -6.37 Million USD | 11643.659% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 4721.013% |
| Fortress Biotech, Inc. | 7.66 Million USD | -9505.558% |
| Lantern Pharma Inc. | -21.7 Million USD | 3492.418% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 766.081% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 8718.177% |
| Incyte Corporation | -3.17 Billion USD | 123.189% |
| IO Biotech, Inc. | -140.69 Million USD | 623.292% |
| Jaguar Health, Inc. | 29.39 Million USD | -2405.073% |
| Novavax, Inc. | -298.29 Million USD | 346.826% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -13695.503% |
| Opthea Limited | 28.15 Million USD | -2514.818% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 4485.407% |
| ContextLogic Inc. | -232 Million USD | 417.356% |
| MiMedx Group, Inc. | -33.9 Million USD | 2271.812% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -7121.834% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 31876.324% |
| NextCure, Inc. | -6.47 Million USD | 11467.392% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 1557.924% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 11642.029% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -5953.193% |
| Vaxcyte, Inc. | -368.22 Million USD | 299.949% |
| PDS Biotechnology Corporation | -32.7 Million USD | 2350.965% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -4161.292% |
| Pharming Group N.V. | 109.8 Million USD | -570.527% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 4332.387% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 520.171% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 4075.549% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 4075.549% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 10469.944% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 12664.266% |
| Acelyrin, Inc. | -216.9 Million USD | 439.445% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 13223.547% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 42806.845% |
| Summit Therapeutics Inc. | 34.67 Million USD | -2023.395% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 10922.666% |
| Senti Biosciences, Inc. | 1.74 Million USD | -42214.138% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 498.829% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 1050.622% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 12245.596% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -737870.712% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -117139.809% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 729.04% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 537.647% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -564.08% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 9792.812% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 670.245% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -10578.882% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 403.786% |
| Immix Biopharma, Inc. | -17.5 Million USD | 4304.882% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 332.478% |
| MEI Pharma, Inc. | -3.7 Million USD | 19972.227% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -5784.949% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -355.21% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -2549.106% |
| Fortress Biotech, Inc. | 7.66 Million USD | -9505.558% |
| Precigen, Inc. | -481 Thousand USD | 153169.854% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -5128.791% |
| AlloVir, Inc. | -62.69 Million USD | 1274.418% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 1423.886% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -1093.958% |
| ImmuCell Corporation | 10.99 Million USD | -6599.075% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 577.642% |
| Onconetix, Inc. | 5.33 Million USD | -13709.898% |
| PureTech Health plc | -167.19 Million USD | 540.358% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 2517.157% |
| Elevation Oncology, Inc. | -19.11 Million USD | 3951.166% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 15098.289% |
| Seer, Inc. | -4.24 Million USD | 17464.764% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 3163.053% |
| Innoviva, Inc. | 255.56 Million USD | -188.096% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 1417.961% |
| ESSA Pharma Inc. | -33.62 Million USD | 2289.861% |
| GlycoMimetics, Inc. | -40.98 Million USD | 1896.453% |
| GT Biopharma, Inc. | -1.02 Million USD | 72212.243% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 1186.21% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -1101.93% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 649.128% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 5413.698% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 2650.104% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 977435.599% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 2485.672% |
| Aptose Biosciences Inc. | -8.19 Million USD | 9084.489% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 23630.258% |
| Soligenix, Inc. | -4.95 Million USD | 14969.263% |
| Century Therapeutics, Inc. | 847 Thousand USD | -86826.328% |
| Kura Oncology, Inc. | -20.11 Million USD | 3759.738% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 1899.018% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 8867.159% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -40316.535% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 23129.903% |
| Autolus Therapeutics plc | -186.59 Million USD | 494.571% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 1593.319% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 366.962% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -2048.553% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -347.938% |
| GRI Bio, Inc. | -1.79 Million USD | 41140.468% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 8296.173% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 2313.868% |
| IGM Biosciences, Inc. | -72.6 Million USD | 1114.057% |
| INmune Bio, Inc. | -25.41 Million USD | 2997.43% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -387.752% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 1553.376% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 4631.043% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 25621.14% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -1836.778% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 1887.704% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -2209.13% |
| Coherus BioSciences, Inc. | 377.95 Million USD | -94.805% |
| Verastem, Inc. | -37.27 Million USD | 2075.068% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 8214.912% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 1519.664% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 4964.658% |
| Histogen Inc. | -7.48 Million USD | 9933.925% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 3507.563% |
| Surrozen, Inc. | -32.66 Million USD | 2354.06% |
| Organovo Holdings, Inc. | -1.5 Million USD | 48956.403% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 17615.597% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -3783.217% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -28044.725% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -17615.736% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 8884.785% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 1794.825% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 5150.923% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 332.415% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 102067.427% |
| Apollomics, Inc. | -27.39 Million USD | 2787.593% |
| Amarin Corporation plc | -191.04 Million USD | 485.399% |
| Mesoblast Limited | 55.96 Million USD | -1215.63% |
| Turnstone Biologics Corp. | -14.58 Million USD | 5148.45% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 3011.063% |
| Synaptogenix, Inc. | -28.66 Million USD | 2668.833% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 78760.897% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -1410.847% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 85504.871% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 10232.919% |
| Exelixis, Inc. | -73.05 Million USD | 1107.893% |
| Better Therapeutics, Inc. | -860 Thousand USD | 85712.326% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 3166.114% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 405.035% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -99927.171% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 9998.53% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -58613.397% |
| Gritstone bio, Inc. | 39.49 Million USD | -1764.437% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 975.455% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 28072.144% |
| Avid Bioservices, Inc. | 169.72 Million USD | -333.792% |
| Insmed Incorporated | 721.62 Million USD | -2.03% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 8154.094% |
| MediWound Ltd. | -5.32 Million USD | 13934.386% |
| OmniAb, Inc. | 9.2 Million USD | -7900.283% |
| Alector, Inc. | -35.63 Million USD | 2166.016% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -756.412% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 15040.463% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -5461.341% |
| Zai Lab Limited | -775 Million USD | 195.002% |
| Revance Therapeutics, Inc. | 340.55 Million USD | -116.196% |
| Aura Biosciences, Inc. | -21.52 Million USD | 3520.516% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 992.66% |
| Immunic, Inc. | -45.34 Million USD | 1723.877% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 481.06% |
| Veracyte, Inc. | -203.82 Million USD | 461.226% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | -15.349% |
| FibroGen, Inc. | 56.76 Million USD | -1196.996% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -8168.007% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 26143.32% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 35662.427% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 83.961% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 22137.294% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 543.63% |
| TG Therapeutics, Inc. | 17.86 Million USD | -4021.968% |
| Galecto, Inc. | -21.21 Million USD | 3570.334% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 3195.506% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 53.086% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 3108.606% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 6498.418% |
| XBiotech Inc. | -200.02 Million USD | 468.091% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 975.455% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -16160.292% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 2187.928% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 1053.49% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -12837.375% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 532.043% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 897.049% |
| Vaxxinity, Inc. | 10.13 Million USD | -7166.739% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 6937.822% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 1216.299% |
| NexImmune, Inc. | -3.13 Million USD | 23595.529% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 21424.522% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 4972.239% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 2816.849% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 8302.559% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 591122.276% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 1914.715% |
| Ainos, Inc. | 4.07 Million USD | -17954.904% |
| Pluri Inc. | 22.82 Million USD | -3125.135% |
| Prothena Corporation plc | -608.34 Million USD | 221.027% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 719.982% |
| Celularity Inc. | 65.19 Million USD | -1029.416% |
| Rallybio Corporation | -24.1 Million USD | 3154.792% |
| Cue Biopharma, Inc. | -33.81 Million USD | 2277.078% |
| MeiraGTx Holdings plc | -40.3 Million USD | 1926.872% |
| Omeros Corporation | 331.17 Million USD | -122.319% |
| Humacyte, Inc. | -22.48 Million USD | 3374.331% |
| Immunocore Holdings plc | -358.59 Million USD | 305.32% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 3095.996% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 2482.661% |
| Blueprint Medicines Corporation | 702.83 Million USD | -4.756% |
| CalciMedica, Inc. | -5.53 Million USD | 13414.033% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 491.173% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 7308.4% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 1938.964% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 2314.134% |
| Pulmatrix, Inc. | -10.41 Million USD | 7167.927% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 12418.32% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 2030.329% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 760.909% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 1328.256% |
| Cytokinetics, Incorporated | 642.37 Million USD | -14.617% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 12744.101% |
| Nutriband Inc. | -251.65 Thousand USD | 292667.264% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 2257.935% |
| Vor Biopharma Inc. | 4.3 Million USD | -17022.465% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 112.198% |
| Evogene Ltd. | -19.63 Million USD | 3849.954% |
| ProKidney Corp. | -56.23 Million USD | 1409.243% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 1612.71% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 8070.673% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 46.018% |
| CorMedix Inc. | -43.05 Million USD | 1810.158% |
| BioLineRx Ltd. | 7.33 Million USD | -9936.341% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 2780.743% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -1495.48% |
| Atai Life Sciences N.V. | -28.55 Million USD | 2678.143% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -32908.582% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 3326.972% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -4051.486% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 1080.72% |
| MediciNova, Inc. | -50.78 Million USD | 1549.813% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 1034.288% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 3273120.671% |
| GeoVax Labs, Inc. | -6.45 Million USD | 11510.397% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 468.463% |
| Biomea Fusion, Inc. | -166.57 Million USD | 542.016% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 511.379% |
| Mereo BioPharma Group plc | -51.46 Million USD | 1530.504% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 876.292% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 350.636% |
| Absci Corporation | -72.59 Million USD | 1114.168% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -16024.967% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 414.057% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 881.507% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 869.38% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 1984.334% |
| Allakos Inc. | -24.97 Million USD | 3048.012% |
| Imunon, Inc. | -4.21 Million USD | 17572.517% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 5094.343% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 643.771% |
| BioAtla, Inc. | -109.01 Million USD | 775.405% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -99927.171% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 78509.585% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -6052.983% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 3572.461% |
| XOMA Corporation | -29 Million USD | 2638.848% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 4546.051% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 8266.216% |
| aTyr Pharma, Inc. | -7.44 Million USD | 9984.092% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 690.733% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 453.695% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 1000.312% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 893.707% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 85793.635% |
| Akari Therapeutics, Plc | -3.84 Million USD | 19248.661% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -45267.585% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 46.681% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 62068.211% |
| UroGen Pharma Ltd. | 4.39 Million USD | -16667.616% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -548.801% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -1023031.653% |
| Orgenesis Inc. | 21.78 Million USD | -3279.848% |
| Entera Bio Ltd. | -10.62 Million USD | 7026.955% |
| GH Research PLC | -78.07 Million USD | 1043.0% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 3403.419% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 2861.792% |
| Xencor, Inc. | 29.64 Million USD | -2383.693% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 37477.476% |
| Replimune Group, Inc. | 1.41 Million USD | -52043.484% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 300729.624% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 682.411% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 62068.211% |
| Portage Biotech Inc. | -4.98 Million USD | 14881.49% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 3273120.671% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 1213.496% |
| OncoCyte Corporation | -6.56 Million USD | 11318.437% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -81943.162% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 16261.626% |
| Purple Biotech Ltd. | -14.13 Million USD | 5307.71% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 3199.284% |
| scPharmaceuticals Inc. | -6.54 Million USD | 11349.29% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 4510.848% |
| HilleVax, Inc. | -165.48 Million USD | 544.914% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 29109.693% |
| Tharimmune, Inc. | -10.93 Million USD | 6832.897% |
| Genprex, Inc. | -6.73 Million USD | 11027.672% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 299.634% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 932.315% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 52652.891% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 22297.105% |
| OKYO Pharma Limited | -826.84 Thousand USD | 89144.903% |
| Savara Inc. | 153 Thousand USD | -481119.608% |
| Curis, Inc. | -23.88 Million USD | 3182.287% |
| Daré Bioscience, Inc. | -5.15 Million USD | 14374.5% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 94978.172% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 11959.955% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -62032.152% |
| BeiGene, Ltd. | -2.25 Billion USD | 132.678% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -5867.225% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 221.056% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 496.725% |
| Erasca, Inc. | -37.21 Million USD | 2078.359% |
| bluebird bio, Inc. | 108.57 Million USD | -578.142% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 57268.259% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -94.395% |
| DBV Technologies S.A. | -126.98 Million USD | 679.801% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 57268.259% |
| Moderna, Inc. | -2.9 Billion USD | 125.327% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 7212.307% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 6874.623% |
| Molecular Templates, Inc. | 707 Thousand USD | -104039.463% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 2446.964% |
| Travere Therapeutics, Inc. | 346.6 Million USD | -112.42% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 997.207% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 902.645% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 2381.439% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 2241.802% |
| MacroGenics, Inc. | -66.98 Million USD | 1199.151% |
| RenovoRx, Inc. | -1.17 Million USD | 62867.775% |
| Adicet Bio, Inc. | -138.78 Million USD | 630.501% |
| Prime Medicine, Inc. | -27.94 Million USD | 2735.074% |
| Aditxt, Inc. | 18.12 Million USD | -3963.08% |
| Adagene Inc. | -87.62 Million USD | 940.224% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 17775.639% |
| Quantum-Si incorporated | -118.55 Million USD | 721.023% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -1944.899% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 9950.782% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 1617.793% |
| SciSparc Ltd. | -2.06 Million USD | 35754.528% |
| Vericel Corporation | 1.27 Million USD | -57555.912% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 6239.796% |
| Minerva Neurosciences, Inc. | 41 Million USD | -1695.585% |
| Generation Bio Co. | 31.44 Million USD | -2241.217% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 519.85% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 2480.966% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -531.484% |
| Invivyd, Inc. | -198.47 Million USD | 470.96% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 915.626% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 30807.328% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 1140.071% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 10887.78% |
| 2seventy bio, Inc. | 181.71 Million USD | -305.176% |
| ADMA Biologics, Inc. | 90.06 Million USD | -717.474% |
| Clene Inc. | 3.34 Million USD | -21943.892% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 8206.243% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 3522.742% |
| GeoVax Labs, Inc. | -6.45 Million USD | 11510.397% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 313.954% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 2931.827% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -314.41% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 18094.719% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -14619.432% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 14234.498% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 665.037% |
| Evaxion Biotech A/S | 5.28 Million USD | -13826.38% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 754.063% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 660.866% |
| Trevena, Inc. | 2.25 Million USD | -32506.997% |
| Surrozen, Inc. | -32.66 Million USD | 2354.06% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 1529.365% |
| Cingulate Inc. | 3.08 Million USD | -23783.935% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 25168.641% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -10144.414% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 8024.314% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 1028.187% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 660.103% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 797.605% |
| Clearmind Medicine Inc. | -3.94 Million USD | 18774.456% |
| Kronos Bio, Inc. | -36.05 Million USD | 2142.12% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -7725.125% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -50393.956% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 1457.022% |
| Statera Biopharma, Inc. | 14.41 Million USD | -5007.14% |
| ImmunityBio, Inc. | 618.22 Million USD | -19.094% |
| Korro Bio, Inc. | -132.94 Million USD | 653.821% |
| Kineta, Inc. | -4.54 Million USD | 16313.741% |
| BioVie Inc. | -17.73 Million USD | 4252.106% |
| Codexis, Inc. | -43.27 Million USD | 1801.523% |
| Celularity Inc. | 65.19 Million USD | -1029.416% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 23333.386% |
| Celcuity Inc. | 6.78 Million USD | -10753.763% |
| Virax Biolabs Group Limited | -3.36 Million USD | 21980.483% |
| Cibus, Inc. | -8.07 Million USD | 9214.459% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 17509.931% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -16010.853% |
| IN8bio, Inc. | -16.38 Million USD | 4592.44% |
| Kodiak Sciences Inc. | -103.87 Million USD | 808.8% |
| Annexon, Inc. | -193.75 Million USD | 479.998% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -2045083.333% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 4307.475% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 21058.326% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 30.164% |
| Eyenovia, Inc. | 1.25 Million USD | -58394.068% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -2636.54% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 22803.238% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 2314.534% |
| Arcellx, Inc. | -296.95 Million USD | 347.936% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 3874.562% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 1350.558% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 3652.207% |
| Moolec Science SA | 117.61 Thousand USD | -625891.362% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 2017.409% |
| Geron Corporation | 14.76 Million USD | -4887.914% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 2041.732% |
| Royalty Pharma plc | 5.65 Billion USD | 86.988% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 620.62% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 10634.001% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 13828.983% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 623.173% |
| Humacyte, Inc. | -22.48 Million USD | 3374.331% |
| Structure Therapeutics Inc. | -124.33 Million USD | 692.144% |
| 89bio, Inc. | -289.05 Million USD | 354.717% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 3016.829% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 41393.662% |
| Genelux Corporation | -6.89 Million USD | 10772.068% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 2470.54% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -780.711% |
| Notable Labs, Ltd. | -9.77 Million USD | 7631.363% |
| Liquidia Corporation | -80.17 Million USD | 1018.312% |
| Mustang Bio, Inc. | -3.73 Million USD | 19807.334% |
| Immunovant, Inc. | -635.22 Million USD | 215.906% |
| Quantum-Si incorporated | -118.55 Million USD | 721.023% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 4291.904% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 17871.325% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -9072.368% |
| Acasti Pharma Inc. | -23 Million USD | 3300.461% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 21965.635% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 4631.043% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 634.533% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 23725.818% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 3411.74% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 4065.028% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 534.945% |
| PepGen Inc. | -60.67 Million USD | 1313.559% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 3304.5% |
| United Therapeutics Corporation | -507.7 Million USD | 245.02% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 3949.556% |
| Solid Biosciences Inc. | -47.75 Million USD | 1641.918% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 85504.871% |
| Immuneering Corporation | -54.94 Million USD | 1440.058% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 17615.597% |
| Silo Pharma, Inc. | -3.52 Million USD | 20991.08% |
| Belite Bio, Inc | -87.27 Million USD | 943.655% |
| XOMA Corporation | -29 Million USD | 2638.848% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 1141.439% |
| Bionomics Limited | 227 Million USD | -224.332% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 733.173% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 29166.956% |
| uniQure N.V. | -102.95 Million USD | 815.162% |
| Cassava Sciences, Inc. | -121.13 Million USD | 707.801% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 17775.639% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -1697.919% |
| Forte Biosciences, Inc. | -11.96 Million USD | 6255.556% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 23895.036% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -694490.566% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 22803.238% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -8168.007% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 10028.074% |
| Altimmune, Inc. | -134.48 Million USD | 647.463% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -271.729% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 29166.956% |
| Compugen Ltd. | -12.9 Million USD | 5805.719% |
| Peak Bio, Inc. | 10.34 Million USD | -7020.452% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 260264.664% |
| Benitec Biopharma Inc. | -50.58 Million USD | 1555.589% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 805.655% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -3647.854% |
| Zura Bio Limited | -99.8 Million USD | 837.697% |
| PolyPid Ltd. | 6.17 Million USD | -11832.998% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -893.343% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -3647.854% |
| Instil Bio, Inc. | 75.35 Million USD | -877.024% |
| argenx SE | -2.02 Billion USD | 136.29% |
| Immunome, Inc. | -97.02 Million USD | 858.81% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 3373.021% |
| Verona Pharma plc | -220.44 Million USD | 433.994% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 1126.255% |
| Shattuck Labs, Inc. | -121.42 Million USD | 706.36% |
| CervoMed Inc. | -7.79 Million USD | 9547.973% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 496.911% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 16936.634% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 658.878% |
| Moolec Science SA | 117.61 Thousand USD | -625891.362% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 32279.782% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -4531.076% |
| AnaptysBio, Inc. | -18.15 Million USD | 4156.338% |
| Design Therapeutics, Inc. | -18.15 Million USD | 4156.562% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 1146.115% |
| NeurAxis, Inc. | 145.7 Thousand USD | -505230.13% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -6455.075% |
| Lumos Pharma, Inc. | -28.49 Million USD | 2684.024% |
| Achilles Therapeutics plc | -126.92 Million USD | 680.084% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 1126.255% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 112381.884% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 3644.2% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -50393.956% |
| Nutriband Inc. | -251.65 Thousand USD | 292667.264% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 5690.054% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 9996.048% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | -116.423% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -3002.027% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 264.539% |
| Palisade Bio, Inc. | -12.06 Million USD | 6203.507% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 624.739% |
| Beam Therapeutics Inc. | -262.72 Million USD | 380.245% |
| Neurogene Inc. | -131.95 Million USD | 657.967% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -3274.89% |
| AEON Biopharma, Inc. | -4.88 Million USD | 15187.418% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 295.197% |
| Sesen Bio, Inc. | -112.55 Million USD | 754.15% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 837.298% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 31459.92% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 1986.604% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 984.064% |
| Athira Pharma, Inc. | -88.99 Million USD | 927.274% |
| Vaccinex, Inc. | -1.28 Million USD | 57263.509% |
| HCW Biologics Inc. | 2.85 Million USD | -25673.521% |
| XOMA Corporation | -29 Million USD | 2638.848% |
| Nektar Therapeutics | 210.24 Million USD | -250.203% |
| Arvinas, Inc. | -313.8 Million USD | 334.629% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -45267.585% |
| Merus N.V. | -192.88 Million USD | 481.714% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -1127.417% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 10712.078% |
| Rezolute, Inc. | -68.16 Million USD | 1180.076% |
| Clene Inc. | 3.34 Million USD | -21943.892% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 5683.271% |
| BeyondSpring Inc. | -13.75 Million USD | 5452.715% |
| Synlogic, Inc. | -6.68 Million USD | 11113.702% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -64826.455% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 8808.054% |
| Peak Bio, Inc. | 10.34 Million USD | -7020.452% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 993.31% |
| Krystal Biotech, Inc. | -350.23 Million USD | 310.221% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -493.165% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 535.671% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 23420.634% |
| MannKind Corporation | 143.89 Million USD | -411.655% |
| Ikena Oncology, Inc. | -109.15 Million USD | 774.508% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 9824.818% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 2324.369% |
| Gossamer Bio, Inc. | 180.35 Million USD | -308.232% |
| CohBar, Inc. | -5.93 Million USD | 12514.422% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 2575.01% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -16024.967% |
| Legend Biotech Corporation | -949.39 Million USD | 177.551% |
| Mural Oncology plc | -255.84 Million USD | 387.78% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -2185.476% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 15729.844% |
| Disc Medicine, Inc. | -358.28 Million USD | 305.5% |
| Champions Oncology, Inc. | 4.81 Million USD | -15200.623% |
| REGENXBIO Inc. | 54.76 Million USD | -1244.336% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 273899.492% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 587.516% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 8269.835% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 1012.542% |
| Vaxart, Inc. | -8.24 Million USD | 9034.183% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 1567.251% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 678.982% |
| Cellectis S.A. | -43.85 Million USD | 1778.864% |
| Longeveron Inc. | -2.9 Million USD | 25418.638% |
| Repare Therapeutics Inc. | -107.85 Million USD | 782.625% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 23.969% |
| Inozyme Pharma, Inc. | 12 Million USD | -6033.505% |
| Revolution Medicines, Inc. | -608.2 Million USD | 221.056% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 59959.024% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 377.714% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 590.609% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 4805.477% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 99595.405% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 107.698% |
| Denali Therapeutics Inc. | -74.86 Million USD | 1083.458% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 6239.796% |
| Veru Inc. | 4.77 Million USD | -15303.154% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 6646.914% |
| Cingulate Inc. | 3.08 Million USD | -23783.935% |
| Passage Bio, Inc. | 4.58 Million USD | -15958.146% |
| Context Therapeutics Inc. | -14.44 Million USD | 5195.327% |
| Exicure, Inc. | 5.84 Million USD | -12487.895% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 419.593% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 1960.667% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -4592.282% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 1351.706% |
| Nuvalent, Inc. | -335.38 Million USD | 319.527% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -42352.205% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 1088.515% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 8381.957% |
| OmniAb, Inc. | 9.2 Million USD | -7900.283% |
| Anew Medical, Inc. | 1.43 Million USD | -51298.533% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -4394.427% |
| Lipocine Inc. | -4.75 Million USD | 15585.367% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 770.381% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -4733.996% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 1553.376% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -2857.842% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 11054.709% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 1218.486% |
| Ocugen, Inc. | -32.52 Million USD | 2363.971% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 960.375% |
| Q32 Bio Inc. | -37.94 Million USD | 2040.197% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 117339.809% |
| Alumis Inc. Common Stock | -13.52 Million USD | 5542.132% |
| Equillium, Inc. | -22.39 Million USD | 3388.076% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 2979.639% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 2356.632% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 297083.24% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -449.28% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -22922.702% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -224069.942% |
| Dominari Holdings Inc. | 195 Thousand USD | -377472.308% |
| Edesa Biotech, Inc. | -5.26 Million USD | 14079.088% |
| vTv Therapeutics Inc. | -8.91 Million USD | 8356.88% |
| Bio-Techne Corporation | 267.74 Million USD | -174.986% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 4642.328% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 723.458% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 8861.942% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 5919.825% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 400.371% |
| Nkarta, Inc. | 57.29 Million USD | -1184.954% |
| BioCardia, Inc. | 212 Thousand USD | -347195.283% |
| Iterum Therapeutics plc | 13.43 Million USD | -5378.985% |